Liquid biopsy identifies residual breast cancer
Using a platform tailored to patients specific cancer mutations, British and US researchers for the first time detected residual disease in breast cancer patients.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1279 entries already.
Entries by Thomas Gabrielczyk
Google maps for tumours and organs
/in News/by Thomas GabrielczykGerman researchers have developed a software that allows to manage and correct the huge amount of data generated by 3D reconstruction of tumours or organs using light sheet microscopy.
Transgenes licenced oncolytic virus fails in Phase III
/in News/by Thomas GabrielczykSillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be […]
Alizé Pharma 3 bags largest EU financing so far
/in News/by Thomas GabrielczykVenture Captital specialist LSP led a 67m Series A financing in peptide developer Alizé Pharma 3.
Better TNF? receptor blockers on the horizon
/in News/by Thomas GabrielczykTwo research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments.
European Commission approves ten GMOs
/in News/by Thomas GabrielczykThe European Commission has authorised ten genetically modified products.
Zambon heading to US market with 500m acquisition
/in News/by Thomas GabrielczykZambon is set to acquire respiratory company Breath Therapeutics for up to 500m to complement its respiratory pipeline and get access to the US market.
Gut microbiome boosts muscle strength
/in News/by Thomas GabrielczykSwedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle.
Curetis lower respiratory tract panel ready for FDA clearance
/in News/by Thomas GabrielczykMolecular diagnostics expert Curetis NV has filed for US FDA clearance of Unyvero LRT to speed up diagnosis of patients with lower respiratory tract (LRT) infections.
Merck and Broad Institute announce CRISPR license agreement
/in News/by Thomas GabrielczykMerck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.